yttrium-90-labelled HMFG1

**Yttrium-90-labelled HMFG1** is a radiopharmaceutical consisting of a murine monoclonal antibody (HMFG1) chemically linked to the beta-emitting radionuclide yttrium-90. HMFG1 targets the tumor-associated antigen MUC1, commonly found on epithelial ovarian cancer cells. The drug is administered intraperitoneally and designed for targeted radioimmunotherapy, delivering cytotoxic radiation directly to cancer cells, minimizing exposure to normal tissues. Developed primarily for adjuvant treatment in epithelial ovarian cancer patients who have achieved complete clinical remission after cytoreductive surgery and chemotherapy, clinical studies found it well-tolerated with reversible myelosuppression as the main toxicity. Its mechanism leverages HMFG1’s specificity for MUC1, allowing yttrium-90 to deliver lethal radiation to tumor cells[1][3][5][6].

Brand names

TheragynTMpemtumomab

Other names

yttrium-90-labelled monoclonal antibody HMFG1yttrium90-labelled monoclonal antibody HMFG1yttrium 90-labelled monoclonal antibody HMFG190Y-muHMFG1yttrium Y 90 monoclonal antibody HMFG1